TLL-018

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameTLL-018
Drug Alias NameTLL-018
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase 2 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase 2
Therapy Area/IndicationsPlaque psoriasisChronic UrticariaUrticaria +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTll Pharmaceutical Llc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Highlightll Pharmaceutical Co Ltd
Inactive CompaniesTll Pharmaceutical Llc
Active IndicationsPlaque psoriasisChronic UrticariaUrticaria +[6] 
Inactive IndicationsPsoriasisColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A